{"groups":[{"description":"Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV","id":"FG000","title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}